JUVISÉ-PHARMACEUTICALS
4.2.2020 10:32:09 CET | Business Wire | Press release
The French specialty pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce its successful syndication of its EUR 213 million debt package supporting the acquisition of Arimidex® and Casodex® from AstraZeneca, with the collaboration of Société Générale and HSBC, acting as Physical Bookrunners and Mandated Lead Arrangers, BNP Paribas, acting as Mandated Lead Arranger and Lazard acting as financial advisor to Juvisé Pharmaceuticals.
On the back of a strong support from both relationship lenders and institutional investors, syndication was wrapped following a successful and oversubscribed early-bird phase. The covenanted financing is comprised of a EUR 128 million TLB alongside a EUR 85 million TLA. This syndication was made possible through the collaboration with Juvisé Pharmaceuticals financial partners, with whom the company relies on long-term partnership characterized by openness and trust.
This successful syndication is another important step in Juvisé Pharmaceuticals development. It reasserts the company ability to leverage all debt capital instruments to fulfil its growth ambition, while keeping the flexibility and independence in decision making allowed by its privately held structure.
Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared, “We are very pleased that our acquisition debt package was successfully syndicated in this oversubscribed early-bird phase and we would like to thank our financial partners for the trust they have shown in our project. We are proud to see that our commitment towards physicians, patients, and our Pharma partners convinced renowned financial institutions to support our ambitious development plan.”
About Arimidex®
and Casodex®
Arimidex®
(anastrozole
) and Casodex®
(bicalutamide
) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians.
On 19th December 2019, Juvisé Pharmaceuticals acquired the rights of Arimidex® and Casodex® in 45 countries in Europe and a number of Middle Eastern and African markets.
About Juvisé Pharmaceuticals
Founded in 2008, Juvisé Pharmaceuticals is specialised in manufacturing, distributing and marketing its own branded pharmaceutical products. Juvisé focuses in offering treatments in: (i) Cardiology, (ii) Neuro-Psychiatry and (iii) Oncology.
The company business model consists in acquiring branded assets from large pharmaceutical companies like Novartis, AstraZeneca or Sigma Tau and optimising value creation through maximization of product life cycle.
11 years after its creation, Juvisé Pharmaceuticals has become a recognized international company commercializing its own treatments in 75 countries around the world.
For more information, please visit juvisepharmaceuticals.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005424/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Expands Commercial Solutions Hub with Integration of Visa Accounts Receivable Manager27.5.2026 14:00:00 CEST | Press release
New integration allows issuers to send virtual card details to suppliers, helping automate virtual card adoption for suppliers at scale Visa Inc. (NYSE: V), a global leader in digital payments, today announced an expansion of the Visa Commercial Solutions Hub (VCS Hub), further strengthening how issuers and suppliers connect to scale virtual card programs. Through a new integration with Visa Accounts Receivable Manager (Visa AR Manager), eligible issuers gain built-in access to end-to-end processing designed to reduce operational friction and accelerate commercial card growth. Virtual cards are among the fastest-growing payment methods in commercial payments yet scaling them remains complex. Issuers often face fragmented supplier connectivity, while suppliers are left with manual reconciliation and inconsistent payment flows. By bringing issuer and supplier networks together, by embedding access to Visa AR Manager in the VCS Hub, Visa is helping to simplify these connections and enable
Parse Biosciences and bit.bio Announce Landmark Alliance27.5.2026 14:00:00 CEST | Press release
Unlocking Cell Fate: Alliance will power AI-driven predictive medicine and human cell manufacturing Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a comprehensive map of transcription factor-driven cell identity, encompassing both cell state and cell fate. This map will serve as the foundational blueprint for developing highly accurate, human-relevant models at scale. By precisely mimicking in vivo biological responses, these models will significantly advance predictive drug discovery and therapeutic development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527668821/en/ The alliance will leverage cutting-edge techniques in massively parallel causal transcriptomics, which allows scientists to test thousands of genetic variables simultaneously to understand what drives cell behavior. bit.bio will contribute its indust
Echodyne Expands Public Safety Radar Applications Through Partnership with Axon27.5.2026 14:00:00 CEST | Press release
Partnership supports safer and more scalable drone operations across law enforcement, homeland security, and Drone as First Responder programs globally Echodyne, the radar platform company, today announced a partnership with Axon (Nasdaq: AXON), the global public safety technology leader, to support a joint focus activity on delivering best in class infrastructure for a range of homeland security and law enforcement UAS applications in the U.S and globally. Under the partnership, Echodyne’s advanced radar technology will continue supporting Axon’s growing ecosystem of public safety drone solutions, enhancing low-altitude airspace awareness for authorized drone operations while helping agencies detect and respond to unauthorized or malicious drone activity. There is increasing demand globally for comprehensive detailed awareness of the low altitude airspace in which drones are proliferating. Drone as First Responder (DFR) operations can deliver critical information to public safety agen
ENGIE and NHOA Energy Break Ground on 320MWh Drogenbos Battery Project in Belgium27.5.2026 13:22:00 CEST | Press release
Construction officially underway, marking a key milestone in the delivery of one of the largest battery storage systems in Benelux NHOA Energy, global provider of utility-scale energy storage systems, joined ENGIE today in marking a significant milestone with the groundbreaking ceremony of a 320MWh Battery Energy Storage System (BESS) at ENGIE’s Drogenbos power station, near Brussels. The ceremony, held this morning in the presence of Hans Bonte, Minister of Energy of the Government of Flanders, Vincent Verbeke, CEO of ENGIE Belgium, Nicolas van den Abeele, Managing Director Renewables & Batteries Benelux of ENGIE, and Giuseppe Artizzu, CEO of NHOA Energy, marked the official start of construction of ENGIE’s third large-scale battery project in Belgium. Awarded under Belgium’s fifth Capacity Remuneration Mechanism (CRM) auction, the project will contribute to the adequacy of the national electricity system under a 15-year contract starting in November 2027. ENGIE has entrusted NHOA Ene
NIQ Launches Survey Groups to Connect Consumer Sentiment with Real Purchase Behavior27.5.2026 13:00:00 CEST | Press release
New integrated capability connects consumer sentiment with real-world purchase data, enabling more confident, action‑driven decisions NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of Survey Groups in NIQ Discover, a new capability that enables brands and retailers to understand not just what is changing in the market, but why. Available immediately within NIQ Discover, Survey Groups build on NIQ Panel Surveys by linking attitudinal insights to real-world purchase behavior from NIQ’s consumer panels—helping clients uncover the motivations behind performance shifts, identify opportunity gaps, and act with greater confidence in an increasingly complex consumer landscape. What’s New: Survey Groups in Discover Survey Groups make NIQ Panel Survey insights easier to access, analyze, and activate within existing workflows. By grouping survey responses with purchase behavior, clients can: Analyze key consumer segments with greater precision Understand the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom